Want to join the conversation?
Excluding 3Q14 clinical trials revenue, $DGX's consolidated revenue was $1.88Bil, up by 0.9% vs. 3Q14 on an equivalent revenue basis. GAAP reported revenues were lower by 1.3%, while diagnostic information services revenue was flat to prior year. Revenue per acquisition was 0.2% better than 3Q14.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?